## 2 Materials and Methods
### Assessments  
All the participants at the study were tested at the dominant hemicorpus using a MyotonPRO device (Myoton AS, Tallinn, Estonia) (Figure 1). \begin{table}
\begin{tabular}{l c c c} \hline \hline
**Characteristics** & \multicolumn{2}{c}{**[PERSON]’s**} & \multicolumn{1}{c}{**Control Group**} & \multicolumn{1}{c}{\(p\)} \\  & **Disease Patients** & **Control Group** & \multicolumn{1}{c}{\(p\)} \\ \hline Number & 49 & 42 & \\ Gender & Male (\%) & 24 (49) & 21 (50) & \\ Female (\%) & 25 (51) & 21 (50) & \\ Age (years), mean (SD) & 69.76 (6.39) & 60.48 (7.62) & 0.63 \\ Weight (kg), mean (SD) & 75.53 (16.45) & 75.47 (12.85) & 0.98 \\ Height (cm), mean (SD) & 168.14 (10.00) & 165.45 (7.45) & 0.15 \\ BMI (kg/m\({}^{2}\)), mean (SD) & 26.83 (4.92) & 27.60 (4.71) & 0.45 \\ Age of disease onset (years), mean (SD) & 60.51 (6.43) & & \\ Disease duration (years), mean (SD) & 9.12 (3.27) & & \\  & Dopamine agonist (\%) & 21 (42.9) & \\  & MAO-B inhibitors (\%) & 15 (30.6) & \\ Medication & Levodopa-in combination with & \multicolumn{1}{c}{} & \\  & dopa-decarboxylase inhibitors & 38 (75.5) & \\  & (benserazide/carbidopa) (\%) & & \\  & Levodopa in combination with & \multicolumn{1}{c}{} & \\  & dopa-decarboxylase inhibitor & \multicolumn{1}{c}{} & \\  & (carbidopa) and COMT inhibitors, & \multicolumn{1}{c}{} & \\  & amantadine (\%) & \multicolumn{1}{c}{} & \\  & COMT (\%) & \multicolumn{1}{c}{} & \\  & I2: [PERSON]’s disease symptoms on & \multicolumn{1}{c}{} & \\  & both sides of the body and no & \multicolumn{1}{c}{} & \\  & difficulty in walking (\%) & \multicolumn{1}{c}{} & \\  & 3: [PERSON]’s disease symptoms on & \multicolumn{1}{c}{} & \\  & both side of the body and minimal & \multicolumn{1}{c}{} & \\  & difficulty in walking (\%) & \multicolumn{1}{c}{} & \\  & 4: [PERSON]’s disease symptoms on & \multicolumn{1}{c}{} & \\  & both sides of the body and moderate & \multicolumn{1}{c}{} & \\  & difficulty in walking (\%) & \multicolumn{1}{c}{} & \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Characteristics of [PERSON]’s disease patients and controls. The MyotonPRO system measures the following five parameters: state of tension (1. natural oscillation frequency characterizing tone or state of tension); biomechanical properties (2. dynamic stiffness, and 3. logarithmic decrement, characterizing elasticity or dissipation of natural oscillation); viscoelastic properties (4. mechanical stress relaxation time (ms), and 5. ratio of relaxation time to deformation time, characterizing creep). The data provided by the device let us analyze the oscillation frequency (Hz), which characterizes the tonus (the intrinsic tension at a cellular level). An increased muscular tonus compared to normal levels alters the conditions of blood feeding of the muscle. The increased tonus is associated with muscular pain, fatigue, overburden, the decrease of physical performance and a late recovery [21]. Dynamic stiffness (N/m) is represented by the capacity of the muscle to endure a force that alters the shape of the muscle. A rigid musculature determines an increased effort for muscular elongation in that area, producing asymmetry between the parts of the body, which disturbs the functional movement rhythm [9; 22]. Elasticity represents the capacity of the muscle to regain its initial shape. The functionality of a muscle can be quantified as efficient only if the muscle regains its shape quickly in the time between two contractions. Lack of elasticity of the muscle produces fatigue more rapidly during effort; the velocity of the movement is limited, and the structure is less elastic [9; 22]. Parkinson's disease patients have changes in the center of gravity with the forward position of the body, a slightly anterior bend of the trunk with the shoulders bent forward, and semi-flexed elbows and knees. The tested musculature was chosen after the examination of the specific posture in these patients. We also considered the muscles that are most affected in usual self-care activities.